ALLARITY THERAPEUTICS INC (ALLR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.98-9.64%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ALLR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
ALLR — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-10-30
Termination of a Material Definitive Agreement. Termination of Common Stock Purchase Agreement On October 28, 2026, Allarity Therapeutics, Inc. (the “Company”) terminated the Common Stock Purchase Agreement, dated January 28, 2026 (the “Purchase Agreement”), by and between the Company and Tumim Stone Capital LLC (“Tumim”), effective as of such date. As previously disclosed, the Purchase Agreement provided the Company with the right, but not the obligation, to sell to Tumim, from time to time…
Why it matters: Higher DRP scores linked to longer survival in an earlier group. A new trial can test if that link holds up.
Watch forNew ovarian trial data show that patients with higher starting DRP scores live longer than those with lower scores.
Also watch forNew ovarian trial data show no link between starting DRP scores and survival, or the score cannot guide patient choice.
Why it matters: The platinum-resistant ovarian trial is the main path to a possible pivotal study. Enrollment and new results will show if it is moving forward.
Watch forA company update gives the patient count or a target date for the platinum-resistant ovarian trial. It also shares new patient data that support more study.
Also watch forThe company reports slow enrollment, a trial delay, or results that do not support further study.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$249 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $762 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,295 loss on $10,000 · 52.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.